Attendee Comments
“After attending several of these meetings as a panellist, speaker and delegate, I continue to find that the content, focus and seniority of the participants results in a very productive experience.” Tony Scullion, Senior Vice President New and International Business Development, Pfizer Inc.
“Definitely one of the best conferences this year.” Hendrik Liebers, Chief Financial Officer, Probiodrug
“Unusual concentration of high level biotech and pharmaceutical executives in a relaxed setting, with interesting, well paced sessions. One of the most useful and enjoyable industry meetings I have ever attended.” Ron Cohen, M.D. President and CEO, Acorda Therapeutics, Inc.
“I appreciate the openness of the big pharma representatives to being contacted/interrupted at the conference. It’s a good event.” Timothy Whitten, President & Chief Executive Officer, Transave Inc.
“Wonderful opportunity to absorb cutting edge thinking on timely topics by leading experts, while meeting with companies keen on accomplishing their business development objectives.” Brian E. Edelman, V.P., Corporate Finance & Investment Banking, Eli Lilly and Company
“The ambience of the event was perfect and the level of attendees excellent. A good experience overall to understand new trends and share strategy.”
Dr Mario Mauzzi, Corporate Business Development Manager, Chiesi Farmaceutica SpA
“Best International meeting I attend, because of its small size and seniority of delegates.” Dr Timothy Rodell, President & Chief Executive Officer, GlobeImmune, Inc.
“A great parenthesis in the middle of the year to reinvigorate your business mind and body.” Yves Ribeill, President & CEO, SCYNEXIS, Inc.
“Business gets done through relationships and this meeting helps develop deep relationships.” Donald deBethizy, President & CEO, Targacept, Inc.
“A good opportunity to meet leaders of biotech companies and discuss potential partnering opportunities.” Ms Barbara Yanni, Vice President & Chief Licensing Officer, Merck & Co, Inc.
“Just the right mix of business and social content to maximize networking.” Dr Andrew Heath, Non Executive Director, Oxford BioMedica
“An excellent overall experience. The access to decision makers to facilitate peer to peer contact and the two way flow of information is outstanding.” Shehnaaz Suliman, Director, Corporate Development Gilead Sciences
“The conference’s intimate and informal nature provides the context for senior level executives from both industry and emerging innovative companies to establish the necessary basis for partnering success.” Brent Vaughan, Chief Business Officer, KineMed Inc.
“A more intimate meeting with senior level attendance.” Gwen Melincoff, Vice President Business Development, Shire Pharmaceuticals
